Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives
Monoclonal antibodies have been the most successful therapeutics ever brought to cancer treatment by immune technologies. The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the introduction of the anti-CD20 antibody rit...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/428253 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560859798306816 |
|---|---|
| author | Giulia Motta Michele Cea Eva Moran Federico Carbone Valeria Augusti Franco Patrone Alessio Nencioni |
| author_facet | Giulia Motta Michele Cea Eva Moran Federico Carbone Valeria Augusti Franco Patrone Alessio Nencioni |
| author_sort | Giulia Motta |
| collection | DOAJ |
| description | Monoclonal antibodies have been the most successful therapeutics ever brought to cancer treatment by immune technologies. The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the introduction of the anti-CD20 antibody rituximab has had a dramatic impact on how we treat this group of diseases today. Despite this success, several questions about how to optimize the use of monoclonal antibodies in NHL remain open. The best administration schedules, as well as the optimal duration of rituximab treatment, have yet to be determined. A deeper knowledge of the mechanisms underlying resistance to rituximab is also necessary in order to improve the activity of this and of similar therapeutics. Finally, new antibodies and biological agents are entering the scene and their advantages over rituximab will have to be assessed. We will discuss these issues and present an overview of the most significant clinical studies with monoclonal antibodies for NHL treatment carried out to date. |
| format | Article |
| id | doaj-art-3d5e579cc57b41f9837d769094748c8f |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-3d5e579cc57b41f9837d769094748c8f2025-02-03T01:26:30ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/428253428253Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and PerspectivesGiulia Motta0Michele Cea1Eva Moran2Federico Carbone3Valeria Augusti4Franco Patrone5Alessio Nencioni6Department of Internal Medicine, University of Genoa, Room 221, V.le Benedetto XV 6, 16132 Genoa, ItalyDepartment of Internal Medicine, University of Genoa, Room 221, V.le Benedetto XV 6, 16132 Genoa, ItalyDepartment of Internal Medicine, University of Genoa, Room 221, V.le Benedetto XV 6, 16132 Genoa, ItalyDepartment of Internal Medicine, University of Genoa, Room 221, V.le Benedetto XV 6, 16132 Genoa, ItalyDepartment of Internal Medicine, University of Genoa, Room 221, V.le Benedetto XV 6, 16132 Genoa, ItalyDepartment of Internal Medicine, University of Genoa, Room 221, V.le Benedetto XV 6, 16132 Genoa, ItalyDepartment of Internal Medicine, University of Genoa, Room 221, V.le Benedetto XV 6, 16132 Genoa, ItalyMonoclonal antibodies have been the most successful therapeutics ever brought to cancer treatment by immune technologies. The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the introduction of the anti-CD20 antibody rituximab has had a dramatic impact on how we treat this group of diseases today. Despite this success, several questions about how to optimize the use of monoclonal antibodies in NHL remain open. The best administration schedules, as well as the optimal duration of rituximab treatment, have yet to be determined. A deeper knowledge of the mechanisms underlying resistance to rituximab is also necessary in order to improve the activity of this and of similar therapeutics. Finally, new antibodies and biological agents are entering the scene and their advantages over rituximab will have to be assessed. We will discuss these issues and present an overview of the most significant clinical studies with monoclonal antibodies for NHL treatment carried out to date.http://dx.doi.org/10.1155/2010/428253 |
| spellingShingle | Giulia Motta Michele Cea Eva Moran Federico Carbone Valeria Augusti Franco Patrone Alessio Nencioni Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives Clinical and Developmental Immunology |
| title | Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives |
| title_full | Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives |
| title_fullStr | Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives |
| title_full_unstemmed | Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives |
| title_short | Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives |
| title_sort | monoclonal antibodies for non hodgkin s lymphoma state of the art and perspectives |
| url | http://dx.doi.org/10.1155/2010/428253 |
| work_keys_str_mv | AT giuliamotta monoclonalantibodiesfornonhodgkinslymphomastateoftheartandperspectives AT michelecea monoclonalantibodiesfornonhodgkinslymphomastateoftheartandperspectives AT evamoran monoclonalantibodiesfornonhodgkinslymphomastateoftheartandperspectives AT federicocarbone monoclonalantibodiesfornonhodgkinslymphomastateoftheartandperspectives AT valeriaaugusti monoclonalantibodiesfornonhodgkinslymphomastateoftheartandperspectives AT francopatrone monoclonalantibodiesfornonhodgkinslymphomastateoftheartandperspectives AT alessionencioni monoclonalantibodiesfornonhodgkinslymphomastateoftheartandperspectives |